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Abstract 
We tested the antimicrobial drug Oxytetracycline-HCl against the infections of the protozoan 
parasite Trypanosoma brucei which causes the disease African Trypanosomosis. 
Oxytetracycline-HCl was used to treat rats infected with the disease at early and late stages of 
infections. Prophylactic administration was also carried out. The results showed that prophylactic 
treatment only did not inhibit the proliferation of the parasite but with continued administration 
kept parasitaemia low. Both prophylactic and early stage treatment of the infection extended the 
lifespan of the animals. Oxytetracycline-HCl was ineffective for the treatment of the late stage of 
infection. Oxytetracycline with its iron chelating property could be a useful inhibitor of 
ribonucleotide reductase, a cell cycle regulated enzyme that in turn regulates cell proliferation. 
Our experiment suggests that   oxytetracycline-HCl could be a good management therapy for the 
African trypanosomosis if administered at the early stage of infection. 
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African trypanosomosis, the human sleeping 
sickness is a great threat to more than 60 million 
people in 36 countries of sub-Saharan Africa 
(WHO, 1998). The disease is caused by 
Trypanosoma brucei, a protozoan parasite 
transmitted from host to host by the blood 
sucking tsetse fly (Seebeck et al., 1999). 
Trypanosomes are a group of unicellular 
haemoflagellates of the genus Trypanosoma 
(WHO, 1986). The parasite lives and multiply in 
the host were it is able to establish its population 
through binary cell division (Vickerman, 1985; 
Ekanem, 2001). During the course of the 
infection there is a constant rising and falling 
parasitaemia resulting from the generation of 
sub-populations with antigenically different 
variant-specific glycoproteins (VSGs) at the cell 
surface (Rudenko et al., 1990). This property 
helps trypanosomes to evade the immune 
system, shield other proteins e.g. permeases on 
the surface from immune attack and inhibit 
phagocytosis (Rudenko et al., 1990). Due to this 
constant change in variable surface 
glycoproteins, termed antigenic variation, it has 
become quite difficult to develop vaccines 
against the disease trypanosomosis (Gray and 
Luckins, 1978; WHO, 1998). Most of the very 
limited drugs currently in use to combat it are 
either too expensive or does not satisfy even the 
minimal standards set today for drug safety and 
efficiency (Seebeck et al., 1999). 
 
Iron is essential to replication and growth 
(Romeo et al., 2001) thus all organisms have an 
ambiguous relationship with it (Hill, 1983; 
Halliwell and Gutteridge, 1990), a relationship 
pathogens and their hosts also share (Cabantchik 
et al., 1999). This dependence of pathogens on 
their hosts’ supply of iron makes them 
susceptible to the potential bacteriostatic effects 
of host iron limitation or chelation (Romeo et 
al., 2001). Much evidence abound to indicate 
that manipulation of the host iron status does 
lead to modulation of the proliferation and 
virulence of bacteria and protozoa (Richardson 
and Ponka, 1997; Mabeza et al., 1999). The 
essentiality of iron cannot be overlooked due to 
its role as prosthetic group in a variety of 
enzymes, electron transport proteins required for 
energy metabolism, for the biosynthesis of 
deoxyribonucleotides required for DNA 
synthesis and repair (Aisen et al., 1999), cell 
viability and proliferation (Richardson and 
Ponka, 1997). It is important in the G1 phase of 
the cell cycle and having its role in DNA 
synthesis liked to the activity of ribonucleotide 
reductase (RNR), an iron-reqiuring enzyme 
responsible for the synthesis of 
deoxyribonucleotides (Thelander and Reichard, 
1979; Nuffer and Cheng 1987; Reichard, 1993; 
Jordan and Reichard, 1998). 
 
Ribonucleotide reductase plays a central role in 
DNA replication, cell division and proliferation 
by providing the deoxyribonucleotide (dNTP) 
precursors required (Nocentini, 1996; Ingram 
and Kinnaird, 1999). It is also the only enzyme 
along the cell division cycle that requires iron 
not as part of a prosthetic group but as part of 
the free iron pool (Thelander et al., 1983; 
Cooper et al., 1996). The role of iron in RNR 
activity has been elucidated through various 
studies by iron chelators to alter cellular iron 
status  (Hoyes et al., 1992, Nyholm et al., 1993; 
Cooper et al., 1996) thus confirming the link 
between RNR activity and iron transport into 
proliferating cells (Chitamber et al., 2000). The 
essentiality of iron in RNR has been proved by 
studies which showed that when iron delivery is 
limited, the tyrosyl radical signal diminishes and 
the R2 subunit exists as a functionally inactive 
apo-R2 protein ( Nyholm et al., 1993). 
 
The structure of Ribonucleotide reductase has 
been described and classed into three different 
classes I (a and b), II and III (Chabes et al., 
2000). Ribonucleotide reductase has been 
reported present in T. brucei (Hofer et al., 1997; 
1998). Trypanosome RNR has binding site for 
iron (Hofer et al., 1997, Dormeyer et al., 1997). 
Unlike mammalian cells, bloodstream forms of 
T. brucei have a low iron content (Schell et al., 
1991) which is attributed to its lack of 
cytochromes and like all living organisms 
trypanosomes require iron for growth (Schell et 
al., 1991; Steverding, 1998). The delivery of 
iron into bloodstream forms of trypanosome is 
mediated by host transferrin that is taken up via 
a unique receptor (Fast et al., 1999). The growth 
of trypanosomes has been successfully inhibited 
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by iron chelation (Breidbach et al., 2002). The 
enzyme has also been reported as a possible 
target for drug discovery against sleeping 
sickness (Ekanem, 2001). 
 
Oxytetracycline belongs to a class of antibiotics 
of naturally occurring tetracyclines and has 
found much extensive use in combating both 
plant (McManus et al., 2002) and animal 
infections (Lents et al., 2002). The tetracyclines, 
oxytetracycline inclusive have been found to 
have strong iron chelating properties (Grenier et 
al., 2000). Oxytetracycline-HCl could be a 
possible drug against sleeping sickness more so 
when a related drug tetracycline-HCl has been 
reported as a possible cheap drug against the 
disease, African trypanosomosis (Ekanem et al., 
2002; Johnson and Ekanem, 2003). In this report 
we have investigated the effect of 
oxytetracycline-HCl on T. brucei infected rats at 
early and late stages of infection. We have also 
assessed the effect of prophylactic treatment of 
the drug against the disease. 




Federe strain of African trypanosomes, 
Trypanosoma brucei was obtained from the 
Veterinary and Livestock Studies Department, 
Nigerian Institute for Trypanosoma Research 
(VLS – NITR), Vom near Jos in Plateau State of 
Nigeria. The parasite was injected into the rats 
intraperitoneally and maintained through 




Albino rats (Rattus novergicus species) of an 
average weight of 230g were used for the 
experiment. They were obtained from the 
Animal house of the Department of 
Biochemistry, University of Ilorin, Ilorin. The 
animals were kept under standard laboratory 
conditions and they were maintained on growers 
mash obtained from Bendel Feed and Flour 
Mills Ltd., Km 100 Benin-Auchi Road, Ewu, 




Research grade reagents were used for the 
experiments. NaCl was a product of BDH 
Chemical Limited, Poole, England. Injectable 
form of Oxytetracycline-HCl 50mg/ml was a 
product of Hamexmedica Limited, Teriot 
Street, London, U.K. 
 
Administration of oxytetracycline-HCl 
 
Oxytetracycline-HCl was injected 
intraperitoneally into the animals twice daily at 
various concentrations taking the weights of the 
rats into consideration. 
 
Inoculation of parasites 
 
The tail of an infected rat was cleaned with a 
damp cloth and the tip of the tail was cut with a 
clean pair of scissors. Then the blood was 
extruded into 0.5ml normal saline solution. The 
extruded blood and saline solution was swirled 
to mix and then drawn into a 1ml syringe. A 
drop of the solution was placed on a microscope 
slide and observed under the light microscope to 
ascertain the presence of the parasite in the 
solution. Inoculation into the peritoneal cavity of 
an uninfected rat was carried out when parasite 
suspension contained 3 or 4 trypanosomes per 
view at x100 magnification. 
 
Parasitaemia (parasite count) 
 
Parasitaemia was determined by counting the 
number of trypanosomes per view under light 
microscope at x100 magnification from a thin 
blood smear obtained from the tip of the tail of 
an infected rat. The parasitaemia was recorded 
at 12 hr interval until the rats died. 
 
Prophylactic treatment  
 
Three groups of three rats were treated with the 
drug for 72 hours at 12 hr interval before 
trypanosome infection and as the infection 
progresses until the death of the animals. The 
dosages used were 15mg/kg, 30mg/kg and 
40mg/kg body weight of the rats.  
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Early stage treatment  
 
Five groups of three rats were treated with 
10mg/kg, 15mg/kg, 20mg/kg, 30mg/kg and 
40mg/kg body weights of the rats from the time 
the parasite was first sighted in the blood until 
the death of the rats. 
 
Late stage treatment 
 
Three groups of three rats were used and treated 
with 10mg/kg, 20mg/kg and 40mg/kg body 
weights of the rats 48 hours after the parasite 





For each experiment control rats (n=3) were 
injected with the parasite and allowed to develop 
without treatment. The parasitaemia was 
recorded until the death of the animals. Another 
group of three rats was also treated with 
oxytetracycline-HCl at 40mg/kg body weight of 





Fig. 1 shows the result obtained when rats were 
treated with oxytetracycline-HCl 72 hours 
before infection. At 15mg/kg body weight, the 
life span of the animals were increased beyond 
day 5 at which the control animals died to day 
10 and the animals lived longer than control by 5 
days. The parasitaemia increased steady from 
the day of infection and peaked the morning of 
day 7 after which it reduced to 3 parasites per 
view on day 8 before the death of the animals on 
day 10 with increased parasitaemia as indicated 
by the count for day 9. 
 
At double the dosage i.e. 30mg/kg, the 
parasitaemia increased steadily from the day 
of infection and reached its peak by the 
morning of day 6 then it dropped until one 
parasite per view was observed on day 10. The 
rats died on the morning of day 13 compared 
with the control animals, their life span were 
extended by 8 days. 
 
With a dosage of 40mg/kg, the parasitaemia 
gave steady increase and peaked on day 5. The 
animals died on day 11 having lived 6 days 
longer than the control animals. The 
parasitaemia was relatively low throughout the 





The results obtained when the infected rats were 
treated with oxytetracycline-HCl immediately 
parasite was sighted are shown in Fig. 2. At 
10mg/kg, the parasitaemia increased steadily 
and the animals died on day 4. At 15mg/kg there 
was a steady increase in parasitaemia till it 
peaked on day 5 when the rats eventually died. 
Treatment at 20mg/kg showed steady increase in 
parasitaemia until day 4 which was followed by 
reduction till day 7 when the parasitaemia 
increased and it reached its peak before the 
death of the rats on day 8. The lifespan of the 
animals were thus extended by 3 days compared 
with the control animals. 
 
At 30mg/kg, the lifespan of the rats were 
increased by 4 days. The parasitaemia 
increased steadily and reached its peak on day 
9 after which death occurred. At 40mg/kg 
dosage, the parasitaemia increased steadily 
and reached a peak on day 11. The animals 
died on day 12 having had their lifespan 




Fig. 3 shows the result of treatment with 
oxytetracycline-HCl 48 hours after parasite was 
first sighted in the blood. At 10mg/kg, the 
parasitaemia increased steadily and peaked on 
day 3. The rats died on day 5. At 20mg/kg 
dosage, the parasitaemia increased steadily and 
reached its peak by day 3 when death occurred. 
At double the dosage i.e. 40mg/kg dosage, the 
parasitaemia increased steadily till it peaked on 
day 5 when the animals died. There was no 
extension in the lifespan of all the animals used 

























Fig.1: Prophylactic treatment with Oxytetracycline HCl. Parasitaemia of T. brucei infected rats 
treated twice daily with Oxytetracycline-HCl 72 hours before infection. The parasitaemia (number 
of cells per view at x100) was monitored until the rats died. Treatments of rats were with 15 
mg/kg, 30 mg/kg and 40 mg/kg body weights of animal dosage. Control rats were infected but not 





























Fig. 2: Early stage treatment with Oxytetracycline-HCl. Parasitaemia of T. brucei infected rats 
treated twice daily with Oxytetracycline-HCl as the infection progressed until death. Treatment of 
rats started on the day parasite was first sighted in the blood with 10 mg/kg, 15 mg/kg, 20 mg/kg, 
30 mg/kg and 40 mg/kg body weight of rats. Control rats were infected but not treated. The 
parasite count was made at 12-hour interval. Each point is an average count of trypanosomes per 
























Fig. 3: Late stage treatment with Oxytetracycline HCl. Parasitaemia of T. brucei infected rats 
treated with Oxytetracycline HCl twice daily as the infection progressed until death. 
Treatment of rats started 48 hours after parasite was first sighted in the blood with 10 mg/kg, 
20 mg/kg and 40 mg/kg body weight of animal dosage. Control rats were infected but nut 




Oxytetracycline-HCl treatment of uninfected 
rats 
 
Uninfected rats that were treated with 
oxytetracycline-HCl for 14 days showed no 
abnormality and no considerable loss in weight 
at the end of the experiment. None of the 
experimental rats survived beyond 14 days. 
DISCUSSION 
When trypanosome enters into a system, the 
parasite proliferates to establish its population in 
the infected host through binary cell division 
(Vickerman, 1985; Ekanem, 2001). They release 
their toxins into the mammalian system 
(Ekanem et al., 1996a,b) and eventually kill 
their host. Iron plays a pivotal role in the 
synthesis of DNA in the trypanosomal system 
through the enzyme ribonucleotide reductase 
(Dormeyer et al., 1997; Hofer et al., 1997). The 
deprivation of a biological system of iron brings 
about the inactivation of the ribonucleotide 
reductase enzyme (Cooper et al., 1996; Chabes 
et al., 2000). It has also been established  
 
 
previously that the deprivation of iron inhibits 
the growth of cells, even those of trypanosomes  
(Fast et al., 1999). Iron chelation has thus been 
adopted as an attractive and possible strategy for 
new antiparasite drugs and treatment of sleeping 
sickness (Ekanem, 2001; Breidbach et al., 
2002). Grenier et al. (2000) reported iron 
chelating properties of oxytetracycline.  
 
Our study revealed that early stage treatment and 
prophylactics at high dosage of 30mg/kg and 
40mg/kg extended the life span of the animals. 
In the case of the prophylactic treatment very 
low parasitaemia with almost total clearance of 
parasite in the system was observed. This is 
probably as a result of the drug chelating iron 
present within the system since it had been 
introduced into the host system long before 
parasite invasion of the system unlike during the 
early stage treatment whereby the drug was not 
administered until the parasite was sighted 
present in the blood. Also, results obtained 
showed that at high dosage of 30mg/kg and 
40mg/kg body weight the parasitaemia was less 
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than those recorded with the lower dosage of 
10mg/kg, 15mg/kg and 20 mg/kg although the 
administration of 15 mg/kg dosage for 
prophylactic treatment brought about death a 
day before the animals treated with 30 mg/kg 
body weight dosage died (Figs. 1 & 2). This 
suggests that high dosage of oxytetracycline is 
considerably effective for removal of the 
parasite from the system. 
 
Oxytetracycline seems to have been recognized 
as a potential trypanocide or combined therapy 
trypanocide judging by the interest it aroused in 
some non-professionals who exploited it to 
combat the disease trypanosomosis. Some 
Maasai pastoralists in Kenya administered 
oxytetracycline with other trypanocides as soon 
as the disease was recognized (Rodericks et al., 
2000) but not as prophylactics. Our study 
established that the use of oxytetracycline-HCl 
for prophylactics kept parasitaemia low and 
considerably extended the lifespan of infected 
animals. Severity of the disease correlates with 
the level of parasitaemia (Murray et al., 1988).      
The late stage of trypanosomosis is usually 
characterized by high parasitaemia, reduced 
packed cell volume, and pronounce haemolytic 
anemia (Murray et al., 1988) due to the lysing of 
the erythrocyte of the animals. The late stage 
treatment by oxytetracycline-HCl was not 
effective since death resulted at about the same 
time as the control (Fig. 3). Obviously, the toxic 
substances released by the parasites into the 
blood stream (Ekanem, 1989; Ekanem et al., 
1986a,b) completely overwhelms the hosts’ 
system ultimately resulting in the death of the 
animals as the disease takes its toll on the 
animals. 
 
We suggest that oxytetracycline-HCl could be 
a useful drug in the management of African 
sleeping sickness since it extends the lifespan 
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